Home » Newsletters » BioWorld Science

BioWorld Science

March 12, 2012

View Archived Issues

New GlyT1 inhibitors patented

Nuvilex provides information on cell encapsulation technology

New nanovector platform allows noncovalent assembly of targeted therapeutics

Promedior closes financing round to advance pipeline

Dr. Falk Pharma obtains European rights to ulcerative colitis drug candidate

Dendritic cell-based vaccine is safe in patients with HIV

Novartis transfers marketing rights for ophthalmic solution

Taiho Pharmaceutical terminates licensing agreement for antipruritic agent

Aegerion Pharmaceuticals provides update on lomitapide NDA

Moberg Derma receives clearance for phase I Limtop trial

New phosphodiesterase 10A inhibitors reported by Evotec

Shionogi & Co. presents novel P2X3 and P2X2/3 receptor antagonists

Avedro submits NDA for corneal cross-linking system

S&T Global designs novel candidate antivirals

New PARP-1 inhibitors with anticancer potential developed in China

Roche divulges new seprase-specific antibodies

Research at Glycotope results in new potential cancer immunotherapies

Novel candidate schizophrenia therapeutics identified

Novel RIPK2 inhibitors reported by GlaxoSmithKline

Roche describes novel potential cancer therapeutics

Janssen unblinds phase III Zytiga study

Teva and OncoGenex amend custirsen advanced prostate cancer program

BioMarin completes enrollment in phase III BMN-110 trial

Transparency Life Sciences in-licenses ACE inhibitor

Novo Nordisk seeks Japanese approval for insulin degludec/insulin aspart coformulation

Peregrine reports topline clinical data on bavituximab

Inviragen reports topline results from HFMD vaccine study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.